Document:

Exhibit 10.9

 

APPENDIX A

 

Amendments to Compensation Policy

 

Itamar Medical Ltd.

 

(The "Company")

 

Compensation Policy

 

As approved by the Company's Compensation Committee on March 10, 2019

 

By the Company's Board of Directors
on March 12, 2019

 

And by the Company's Shareholders at a Meeting of the Shareholders on May 29 2019

 

The definitions and terms in this Compensation
Policy shall have the definitions assigned them in the Companies Law of 1999 (hereinafter: the "Companies Law"), unless
otherwise defined in the Compensation Policy.

 

1.      General

 

The Companies Law-1999 (hereinafter:
the "Companies Law")sets forth provisions, which addresses regulating the structure of compensation to officers
in publicly held companies and in bond companies, as well as establishes a special process for its approval. In accordance with
the Amendment, the Compensation Committee and the Board of Directors of the Company adopted this Compensation Policy.

 

The considerations which guided
the Compensation Committee of the Company (hereinafter: the "Compensation Committee")and the Company's Board
of Directors in adapting the policy are advancement of the Company's objectives, its workplan, and its policy through the perspective
of the current year and with a long-term view; creating appropriate incentives for officers in the Company taking into account,
inter alia, the Company's risk management policy; creating congruence between the officers' interests and the interests
of the Company's shareholders; the Company's size and the character of its activities; as well as regarding [sic] terms
of service and employment that include variable components — the officer's contribution to achieving the Company's goals,
to maximizing its profits, and to maximizing the Company's value, all with a long-term view and according to the officer's role.

 

 

 

    31

     

    

 

The Compensation Policy
was drafted taking into account the character of the Company as a company active in the field of research and development,
marketing, and sale of medical devices, taking into account the scope of the Company's current activities, its being a dual
listed company traded on the biomed index of the Tel Aviv Stock Exchange Ltd. (hereinafter: the "Stock Exchange")
and the Nasdaq stock Exchange in the U.S. (hereinafter: the "Nasdaq"), taking into account the Company's
strategy to increase the scope of the Company's activities according to the Company's business plans and strategies.

 

The principles of the
Compensation Policy were formulated after internal deliberations that took place within the Company's Compensation Committee
and Board of Directors in consultation with external advisors. The principles of this policy were intended to ensure that the
officer's compensation will be consistent with the Company's interests and its total organizational strategy while taking
into account the Company's risk management policy and, at the same time, will result in increasing the officers' sense of
identity with the Company and its activities, will increase their satisfaction and motivation, and will result in retaining
the officers in the Company over time. The compensation principles are based on targets and indices that are derived, inter
alia, from various Company plans, as determined by the Board of Directors from time to time.

 

The components of the Compensation Policy will
address each of the following:

 

		A.	Fixed components: Salary, social benefits (such as: beneficial pension arrangement, disability insurance, continuing  education fund, vacation days, convalescence days, and sick days), benefits accompanying salary (such as: vehicle, mobile phone, mobile computer, Internet connection, financing participation in professional conferences, professional literature, professional liability insurance, including grossing up the value of imputing the benefit for tax purposes), and may include a signing bonus and a relocation bonus as well as severance payments (bonus, payment, reward, competition, or any other benefit, there are given to an officer with respect to the end of his position in the Company).

 

 

    32

     

    

 

		B.	Variable components: Different types of bonus including, inter alia, an annual bonus,
a special bonus, etc.
	 	 	 
		C.	Variable equity components: Options, shares, restricted shares (RS),
restricted share units (RSUs), and so forth, that are issued in the framework of equity-based reward programs that have been adopted
and/or will be adopted in the future by the Company.
	 	 	 
		D.	Insurance, release, and indemnification: Directors and officers liability
insurance (both during the regular course of business as well as with respect to one-time runoff events), release from liability
for officers, in advance and retroactively, and grant of an undertaking to indemnify the officer in advance and retroactively.

 

The provisions of this
Compensation Policy apply to the officers in the Company only, as defined in the Companies Law.

 

The Compensation Policy
is worded in the masculine for the sake of convenience only, but its provision shall apply equally regarding women and men, without
differentiation and without change.

 

It is clarified that anywhere
in the Compensation Policy where it indicates annual wage (gross)/base salaries, the total actual cost to the Company, will also
include payment of social and related benefits to the extent required by law.

 

It is emphasized that this
policy does not grant rights to the Company's officers, and the officers in the Company shall not have an inherent right based
on the adoption of this Compensation Policy to receive any of the compensation components specified in the Compensation Policy.
The compensation components to which the officers will be entitled will be solely those approved individually regarding each officer
by the organs empowered to do so by the Company.

 

2.       Principles
of the Method for Determining Compensation

 

		2.1.	When the Compensation Committee and Company Board of Directors examine and
approve the terms of service and employment of an officer (including updating the terms of service and employment, such as salary,
of an officer who is already serving), they will address, inter alia, the following topics, to the extent they are relevant
to the officer:

 

 

    33

     

    

 

	 	2.1.1.   	The education, qualifications, expertise, professional experience, and achievements of the officer.
	 	 
	 	2.1.2.  	The officer's position, his fields of responsibility, and his expected contributions to achieving the Company's goals.
	 	 
	 	2.1.3.  	The officer's prior salary agreements.
	 	 
	 	2.1.4.   	The terms of employment of corresponding functionaries in the Company.
	 	 
	 	2.1.5. 	To the extent necessary, and the Compensation Committee's discretion, a comparison shall be made to the salary common in the relevant market for similar positions in similar companies.

 

3.       Ratio
Between a Fixed Component and a Variable Component

 

The ratio between the maximal
annual costs of the fixed components and the maximal annual cost of the variable components for officers in the Company as determined
in the framework of this Compensation Policy is as follows:

 

	 	 	 	Percentage of the
                                                                                           Fixed
 Component Out of 
 the Total Compensation 
 (%)	 	 	 	Percentage of the Variable
 Components (Bonuses and 
 Equity) Out of the 
 Total Compensation (%)	 
	Active Chairperson of
the Board of Directors	 	 	47%-100%	 	 	 	0%-53%	 
	External and independent directors	 	 	18%-100%	 	 	 	0%-82%	 
	Directors who are not an active chairperson of the Board of Directors or external/independent directors	 	 	18%-100%	 	 	 	0%-82%	 
	CEO	 	 	32%-100%	 	 	 	0%-68%	 
	Other officer (who is not a director or CEO)	 	 	31%-100%	 	 	 	0%-69%	 

 

 

 

    34

     

    

 

	4.	The Fixed Component

 

4.1.       Base
Salary

 

	 	4.1.1.	Active Chairperson of the Board of Directors

 

	 	4.1.1.1.	 The total annual payment with respect to the services of an active chairperson (gross) paid to an active chairperson of the Board
of Directors with respect to the provision of services to the Company will be determined by the Compensation Committee, the Company's
Board of Directors, and the general meeting of the Company's shareholders, and will not exceed $150,000 (at the exchange rate
as it will be from time to time) for a 100% [full-time] position. In the event of the joint service of two active chairpersons
of the Board of Directors, the cumulative annual payment (gross) with respect to the provision of the services by the two active
chairpersons of the Board of Directors shall not exceed the above sum.
	 	 
	 	4.1.1.2.	Similarly, the Company shall be entitled to grant an active chairperson of the Board of Directors Securities at fair value as
specified in Section 6.3, below.
	 	 
	 	4.1.1.3.	 The Compensation Committee and the Board of Directors of the Company shall be entitled to approve and to bring about the approval
by the general meeting of an annual update to the annual payment with respect to an active chairperson's services paid to an active
chairperson of the Board of Directors, subject to said payment increasing, at most, by five percent (5%) more than the amount
specified in Section 4.1.1.1, above, during the course of the effective period of this Compensation Policy.
	 	 
	 	4.1.1.4.	Additionally, a chairperson of the Board of Directors (active and inactive) will be entitled to reimbursement for reasonable expenses
actually paid in the framework of his/her duties in exchange for presentation of receipts, all in accordance with Company practice.

 

 

 

    35

     

    

 

	 	4.1.2.	Directors (Other Than an Active Chairperson of
    the Board of Directors)

 

	 	4.1.2.1.	The
    remuneration to external directors and independent directors in the Company will be relative remuneration or annual remuneration
    and per meeting remuneration (including in the event of a written resolution or telephone call) as well as reimbursement for
    expenses, that shall be determined in accordance with the provisions stipulated in the Companies Regulations (Rules Regarding
    Remuneration and Expenses for an External Director) of 2000 (hereinafter: the "External Directors Regulations"),
    as they may be from time to time.
	 	 	 
	 	4.1.2.2.	Similarly,
    the Company shall be entitled to grant external directors and independent directors Securities in accordance with the External
    Directors Regulations and at fair value as specified in Section 6.23, below.
	 	 	 
	 	4.1.2.3.	The
    Company shall be entitled to pay special compensation to an expert director which will be relative remuneration or annual
    remuneration and her meeting remuneration to an expert director (including in the event of a written resolution or telephone
    call) as well as reimbursement for expenses, that shall be determined in accordance with the provisions stipulated in the
    External Directors Regulations, as they may be from time to time.
	 	 	 
	 	4.1.2.4.	The
    remuneration that will be paid to directors who are not external directors, independent directors, and/or an active chairperson
    of the Board of Directors (annual remuneration and per meeting remuneration) will not exceed what is stated in the External
    Directors Regulations, as they may be from time to time. Similarly, the Company shall be entitled to grant such directors
    Securities at fair value as specified in Section 6.2, below. The total payment granted to each such director (including variable
    components) will not exceed the remuneration actually paid to external directors.1
	 	 	 
	 	4.1.2.5.	 Additionally, directors in the Company will be entitled to reimbursement for reasonable expenses actually paid in the framework of their duties in exchange for presentation of receipts, all in accordance with Company practice.  

 

1
     To the extent the compensation to external directors is not equal, including if one of the external directors is entitled
to a supplement based on his being an expert external director, then the compensation to an ordinary director may be in the amount
of the higher compensation.

 

 

 

    36

     

    

 

	 	4.1.3.	Company CEO

 

	 	4.1.3.1.	The annual salary (gross) of the CEO of the Company will be determined by the Compensation Committee, the Company's Board of Directors, and the general meeting of the Company's shareholders, and will not exceed US $360,000 (at the exchange rate as it will be from time to time) for a 100% [full-time] position.
	 	 	 
	 	4.1.3.2.	The Compensation Committee and the Board of Directors of the Company shall be entitled to approve and to bring about the approval by the general meeting, subject to the provisions of law, an annual update of the annual salary of the Company's CEO, provided such increase does not exceed five percent (5%) of the amount specified in section 4.1.3.1 above, during the course of the effective period of this Compensation Policy. In addition, and without limitation to the provisions of the Companies Law, as at the date of approval of this Compensation Policy or as shall be in effect from time to time, the Compensation Committee may approve, pursuant to section 272 (d) of the Companies Law, (without a need for the approval of the Board of Director or the general meeting of shareholders), an immaterial annual update of the annual salary of the Company's CEO, provided that such increase does not exceed five percent (5%) and fifteen percent (15%) in the aggregate, of the amount set forth in section 4.1.3.1 above, and provided further that it is a change of currently existing terms/transaction, that the Compensation Committee determined that the update is indeed not material compared to the currently existing terms/transaction of the Company's CEO and provided further that such update is in compliance with the terms of the current Compensation Policy.

 

 

 

    37

     

    

 

	 	4.1.3.3.	In
                                         the framework of determining the Company CEO's salary, the members of the Company's Compensation
                                         Committee and Board of Directors may take into consideration, inter alia, the
                                         salaries of CEOs in other dual listed publicly traded companies similar in size or character
                                         to the Company (hereinafter: the "Comparison Companies") as well as
                                         the Company's financial performance and the CEO's contribution to the Company.
	 	 	 
		4.1.3.4.	Additionally,
                                         the Company CEO will be entitled to reimbursement for reasonable expenses actually paid
                                         in the framework of his/her duties in exchange for presentation of receipts, all in accordance
                                         with Company practice.

 

	 	4.1.4.	Officers

 

		4.1.4.1.	The annual salary (gross) of each of the officers in the Company will be determined by the Compensation
Committee and the Company's Board of Directors, and will not exceed NIS 846,000 for a 100% [full-time] position.
	 	 	 
	 	4.1.4.2.	The Compensation Committee and the Board of Directors of the Company shall be entitled to approve an annual update of the annual
salary of the Company's officers, subject to said annual salary increasing, at most, by five percent (5%) more than the amount
specified in this section, above, during the course of the effective period of this Compensation Policy.

 

 

    38

     

    

 

	 	4.1.4.3.	
In the framework of determining the salary of the Company officers, the members of the Company's Compensation Committee and Board
of Directors may take into consideration, inter alia, the salaries of officers in equivalent positions in the Comparison
Companies as well as the Company's financial performance and the officer's contribution to the Company.
	 	 	 
		4.1.4.4.	Additionally, the officers will be entitled to reimbursement for reasonable expenses actually paid
in the framework of their duties in exchange for presentation of receipts, all in accordance with Company practice.

 

	 	4.1.4.4.4.4.1.4.5.	Notwithstanding the provisions of this Compensation Policy, the Company CEO may approve an immaterial update in the terms of
service and employment of officers reporting to him, provided such update is in line with the provisions of this Compensation
Policy and its aggregate scope does not exceed five percent (5%) of the total compensation of such officer on the approval
date of this Compensation Policy (or on the date of approval of the officers' engagement, whichever is later). Such an
immaterial update, approved by the Company CEO as aforesaid, shall be reported to the Compensation Committee on its first
meeting following such approval.

 

4.2.       Social
and Associated Benefits

 

		4.2.1.	The
                                         Company shall be entitled to grant the officers, other than the directors, social and
                                         associated benefits as specified below, that shall be determined in comparison to the
                                         terms common in the market for officers in parallel positions and in accordance with
                                         the Company's policies, such as: (A) a beneficial pension arrangement (including the
                                         option for an arrangement according to a section of the Severance Pay Law of 1963) [sic];
                                         (B) disability insurance; (C) health insurance; (D) contributions to a continuing
                                         education fund; (E) vacation days; (F) convalescence pay; (G) sick days; (H) a Company
                                         vehicle; or (I) taxation gross up.
	 	 	 

		4.2.2.	Similarly, the Company shall be entitled to grant the officers and directors perquisites accompanying
wages such as: Mobile phone, mobile computer, Internet connection, and so forth.

 

 

    39

     

    

 

4.3.       Signing
Bonus and Relocation Bonus

 

	 	4.3.1.	The Company shall be entitled, under circumstances that shall be approved by the Company's Compensation Committee and by the Board
of Directors as exceptional circumstances according to which recruitment of such officer is of great importance to the Company,
to offer the officer a signing bonus or a bonus for relocation, all subject to obtaining the approvals required by law.
	 	 	 
		4.3.2.	The total signing bonus shall not exceed the sum of 8 months' base salary
that is determined in relation to the relevant officer. The Company shall be entitled to determine, on the date the signing bonus
is granted and at the discretion of the Compensation Committee and the Board of Directors, that the officer will be required to
return all or part of the signing bonus granted him to the Company to the extent that he does not complete a minimum term of service
in the Company.
	 	 	 

		4.3.3.	A bonus for relocation will be granted in the event in which the officer
relocated to a different country in order to work for the Company. The total bonus for relocation will be calculated according
to the officer's actual expenses with respect to relocating opposite the presentation of receipts and, in any event, will not exceed
a sum equal to US $90,000 in relation to the Company's CEO and to US $50,000 in relation to an officer who is not a CEO, and may
be paid in cash or as share-based compensation, at the discretion of the Compensation Committee and the Board of Directors of the
Company.

 

 

    40

     

    

 

4.4.          Severance Pay

 

In any event of a termination
of an employment relationship (other than in the event of the termination of an officer under circumstances which, in the opinion
of the Compensation Committee and the Board of Directors, grant the Company the right to terminate him without severance pay under
the law), the officer will be entitled to severance pay under the law or, alternatively, in the amount of the payments deposited
on his behalf with respect to severance pay into a provident fund, pension funds, etc., in accordance with the provisions of Section
14 of the Severance Pay Law of 1963, all at the discretion of the Company and according to what is stipulated in the employment
agreement. Notwithstanding the above, the Company shall be entitled to stipulate in the employment agreement with the officer (whether
on the date the employment agreement is executed or whether the framework of an update to the employment agreement) a higher amount
in severance pay than that which is due to the officer under the law, up to a cap equal to four (4) monthly salaries above the
foregoing severance amounts, which will be determined taking into consideration the officer's role, position, the number of years
of his employment by the Company, and so forth.

 

4.5.          Prior Notice

  

	 	4.5.1.
	The Company shall be entitled to give the CEO of the Company a period of prior notice of up to six (6) months. The Company shall
be entitled to give an officer in the Company who is not a CEO a period of prior notice of up to four (4) months. The Company shall
be entitled to waive the employment of an officer (including the Company CEO) in the Company during the course of the prior notice
period, in whole or in part, provided that it continued to make all of the payments he is due under his employment agreement. Alternatively,
the Company shall be entitled to terminate the officer's (including the Company CEO) employment without prior notice provided that
the Company pays the officer (including the Company CEO), on the date of the termination of his employment, payments that shall
not be less than the payments he is owed in lieu of the prior notice period.
	 	 	 
		4.5.2.	The Compensation Committee and the Board of Directors will be entitled to grant approval to an
officer (including the Company CEO) for the officer to be entitled to monetary and/or equity bonuses with respect to the prior
notice period and that the prior notice period will count toward the vesting of equity compensation, to the extent it has been
granted him.
	 	 	 

		4.5.3.	The prior notice period granted each officer (including the Company CEO) shall be determined in
the employment agreement with the officer (including the Company CEO) (whether on the date the employment agreement is executed
or whether within the framework of an update to the employment agreement), or it may be approved by the appropriate organs of the
Company at a later date.

 

 

    41

     

    

 

5.       Variable
Component Bonus, Special Bonus, and Commissions

 

5.1.          Targets
for an Annual Bonus for an Officer (Including the Company CEO and Not Including Directors)

 

The Company is entitled
to grant an officer (including the Company CEO) an annual bonus that will be calculated according to the level of his having met
targets and indices and various types, in whole or in part, all as specified below. The said targets and indices with respect to
the Company CEO, shall be approved by the Compensation Committee and the Board of Directors.

 

The Company may grant officers
who report to the Company CEO (excluding directors) an annual bonus, which will be calculated taking into consideration the level
of the respective officer's having met targets and indices and various types, in whole or in part. Such targets and indices shall
be determined solely by the Company's CEO, as detailed hereunder.

 

5.1.1.     
Company Targets — Company indices are economic indices for the Company's performance, as follows: (A) the
Company's share price or the Company's value, on the exchange on which it is traded; (B) the Company's income from sales; (C)
operational profit/loss;2 (D) income from the sales of any of the Company's products; (E) income from sales of the
Company's products, in whole or in part, in a particular territory/market; (F) gross profit; (G) net profit/loss; (H) EBITDA.
The weight that will be given to (a) Company target(s) that is chosen is 0%-100%. Targets B through H, above, will be calculated
on the basis of the Company's audited consolidated financial statements.

 

	2	 	For the purpose of the above Board of Directors' review, operational profit/loss will be taken after neutralizing depreciation and amortization, changes in allocations for lost and doubtful debts, expenses with respect to share-based payment, and the effect of one-time events.

 

 

    42

     

    

 

5.1.2.         Personal
Targets — Indices that will be determined in relation to each of the officers (including the Company CEO), in
accordance with the position filled by that same Officer and the Company's work plan, and which may include, inter alia, as
applicable to the relevant organizational departments: Meeting targets for development, decreasing manufacturing costs,
improving product quality as measured by the quantity of malfunctions, improving financial indices at the organizational unit
level such as sales and profitability, meeting client installation accrual targets, breaking into new markets, compliance
with sales mix, cash balances, collection, meeting expense targets, meeting financing targets, closing distribution
transactions, implementing distribution transactions, client satisfaction index, employee satisfaction index, employee
turnover target, regulatory filing and approval according to plan, clinical trials and recruitment of patients for clinical
trials, meeting the number of launches of new products, raising capital (including by means of a public offering/initial
public offering) in relation to the relevant organizational units), reduction of inventory quantities and shortening
inventory cycles, publishing clinical articles according to plan, placing the Company's products in guidelines, meeting
success targets for customer training and marketing events, meeting supply targets and milestones for receiving insurance
coverage. The weight that will be given to (a) personal target(s) that is/are chosen is 0%-100%.

 

5.1.3.
       Manager's Evaluation — Performance evaluation by the Board of Directors of the Company (in relation to a CEO) or by
the CEO of the Company (in relation to all other officers). The evaluation will address, inter alia, criteria which are
not financial, the long-term contribution of the officer and to his long-term performance. Within the framework of determining
the targets of the Company CEO, the weight that will be given this category is up to 20%.

  

 

    43

     

    

 

The Compensation Committee
and the Board of Directors (with respect to the Company CEO) or the Company CEO (with respect to officers reporting to him) will
determine the number and composition of the targets as well as the weights of the targets in the same category (for example: If
2 personal targets are chosen, then the Board of Directors will determine the weight of each of them provided that their total
weight not exceed 100%). The Compensation Committee and the Board of Directors, or the Company CEO, as set forth above, may condition
the entitlement to compensation in meeting one target and may determine that all targets shall be of only one type.

 

Specifics of the targets
in each measurement category as well as the relative weight of each of the measurement categories will be coordinated for each
officer separately (to the extent that targets were indeed determine for each officer, as aforementioned), according to the officer's
seniority, role and according to the organizational unit to which he belongs and/or which he supervises.

 

5.2.       Date of Determination of the Criteria

 

In relation to officers
who report to the CEO of the Company, to the extent that their annual bonus will be contingent upon meeting targets, the weight
of each of the different measurement categories will be determined each year in advance, with the approval of the CEO. In relation
to the CEO of the Company, the targets and the weight of each of the different measurement categories will be determined at least
each year in advance by the Board of Directors of the Company and with the approval of the Compensation Committee. Notwithstanding
the above, it shall be possible to determine said weights for a number of years in advance subject to the authority of the relevant
organ to update, to the extent necessary, these weights at the start of each calendar year.

 

5.3.
        Maximum Annual Bonus — The maximum amount of the annual bonus shall not
exceed the sum of twelve (12) months' salary (in terms of cost to the Company) for a Company CEO, and nine (9) months' salary
(in terms of cost to the Company) for any other Officer who is not a director or CEO and who resides in Israel.

 

5.4.         Method
of Payment of the Annual Bonus — The annual bonus may be paid, in whole or in part, in cash or in equity-based payment
(for example, shares, restricted shares, options, etc.) at the discretion of the Compensation Committee and the Board of
Directors of the Company.

 

 

    44

     

    

 

5.5.        The
annual bonus will be paid immediately after the Company has the final data in relation to the relevant criterion and in
relation to the criteria under the financial statements — after publication of the Company's audited annual financial
statements.

 

5.6.        Calculation
of the Bonus in Cash Upon Ending the Employment Relationship — In the event in which the employment relationship between
the officer and the Company comes to an and as a result of termination of the officer during the course of a calendar year (provided
that is not termination under circumstances that do not entitle the officer to severance pay): The terminated officer shall be
entitled to a relative portion of the annual bonus only with respect to meeting the criteria under the financial statements, which
will be calculated pro rata, in accordance with the period during the respective calendar year, during which the respective officer
was employed by the Company.

 

5.7.        In
the event in which the employment relationship between the officer and the Company comes to an end as the result of the
resignation of the officer during the course of the calendar year (provided that it is not resignation under circumstances
that had it been the termination of the officer, he would not have been entitled to severance pay): The resigning officer
shall be entitled to an annual bonus in relation to a particular calendar year solely with respect to meeting criteria under
the financial statements and only to the extent that he served as an officer in the Company up until March 31 the following
year, where the amount of the bonus will be calculated according to what is stated in Section 5.4.2(A) through (C),
above.

 

5.8.       Regarding calculation of the equity bonus
at the end of the employment relationship, see Section 6.9, below.

 

5.9.         Special
(Discretionary) Bonus to Officers Reporting to the CEO

 

Subject to the principles for determination of a bonus set forth in
this section above, including the cap applicable to such bonus, and mutatis mutandis:

  

 

    45

     

    

 

5.9.1.
      The Compensation Committee and the Board of Directors of the Company may determine that, in addition to the annual bonus or instead
of the annual bonus, an officer who reports to the Company CEO, may be eligible to a discretionary bonus up to a cap of three (3)
salaries.

 

5.9.2.
      As part of the variable compensation component of officers reporting to the Company CEO, the Company CEO may approve in respect
of each calendar bonus year, a discretionary bonus, which shall not exceed three (3) monthly salaries of the respective officer.
Such a bonus shall be reported to the Compensation Committee at its first meeting following such approval by the Company's CEO.

 

5.10.       Special
(Discretionary) Bonus to the company CEO

 

5.10.1.   In
addition to the annual bonus, the Company shall be entitled to pay to the Company's CEO, a special bonus, which shall be determined
at the discretion of the Compensation Committee and the Board of Directors of the Company, including for the Company's CEO performance
which cannot be measured or in light of the special and exceptional contribution of the Company's CEO, such as in connection with
closing a deal of exceptional scope or the achievement which it embodies. The special bonus will be granted to the Company's CEO
subject to approval of the Compensation Committee and the Board of Directors.

 

 

    46

     

    

 

5.10.2.
    A special (discretionary) bonus as aforementioned may be paid to the Company's CEO only once per year. The amount of the special
bonus Discretionary bonus (together with the reminder to the discretionary components of the variable compensation, to the extent
there are such components) shall not exceed (1) three (3) months' salary (in terms of cost to the Company) or (2) 25% of the total
actual variable compensation components of the Company's CEO.3

 

5.9.3.5.10.3.   The
special bonus may be paid, in whole or in part, in cash or in equity-based payment (for example, shares, restricted shares, options,
etc.) at the discretion of the Compensation Committee and the Board of Directors of the Company.

 

5.11.       Commissions

 

5.11.1.   
In addition to the annual bonus and the special bonus, the Company shall be entitled to pay the officers in the fields of sales,
marketing and business development, commissions in accordance with the Company's procedures which shall be approved by the Compensation
Committee and the Board of Directors of the Company.

 

5.11.2.    The
amount of the commissions awarded to officer as stated will be calculated as a percentage of the amount of the income from the
Company's sales or income from the sales of any of the Company's products or income from the sales of the Company's products,
in whole or in part, in a particular territory/market, that shall be determined in advance, each calendar year in relation to
the following year, by the Compensation Committee and the Board of Directors of the Company. In any case, the amount of commissions
awarded to each officer shall not exceed the sum of NIS 700,000 per year.

 

 

3            In
accordance with Section 5.1.3, above, 20% of the total annual bonus to the Company CEO may be awarded in accordance with the evaluation
of the Board of Directors of the Company, where the maximal annual bonus stands at nine months' salary in relation to the Company's
CEO, see Section 5.3, above) (hereinafter in this footnote: the "Discretionary Component in Relation to the Annual Bonus").
It is clarified that in any event, the amount paid to the Company CEO with respect to the Discretionary Component in Relation
to the Annual Bonus together with the amount of the special bonus as stated in Section 5.9.2, with respect to that same calendar
year, shall not exceed the higher of: (1) three (3) months' salary (in terms of cost to the Company) for each of the officers
in the Company or (2) 25% of the total variable components due to the Company's CEO.

 

 

    47

     

    

 

5.12.        Discretion Regarding Reducing a Bonus

 

The Compensation Committee
and the Board of Directors of the Company shall be entitled, in exceptional cases, at their discretion, to reduce or cancel a bonus
or commissions to an officer.

 

6.       Variable
Equity Component

 

6.1.       General

 

The Company shall be
entitled to adopt, from time to time, plans for distributing options to be exercised for shares in the Company, plans for
granting shares, restricted shares and/or restricted share units (RSUs) and so forth (in this section: "Securities"),
to the officers, with the purpose of maintain the officers with the Company for the long term as well of incentivizing the
officers in the Company to meet the annual and perennial work plan's targets or any other target determined by the
Compensation Committee and the Board of Directors of the Company (including a share price target or company value target on
the exchange on which the Company's shares are traded), all in accordance with the terms specified in this Compensation
Policy, below inn connection with officers.

 

The Company shall be entitled
to grant Securities based such plans including to officers, from time to time, in accordance with the education, qualifications,
expertise, professional experience, position, areas of responsibility, and measure of contribution to the Company of the relevant
officer.

 

 

 

    48

     

    

 

6.2.         Fair Value — The fair value
of the Securities that will be granted to each Officer on the grant date, in annual terms, based on a linear calculation,
shall not exceed a total of twenty four (24) months' salary (in terms of cost) for the CEO of the Company and a total of
twelve (12) months' salary (in terms of cost) for any other officer who is not a director or CEO.4 It is clarified
that the above fair value ceilings do not include an annual bonus or special bonus paid as equity compensation, regarding
which the ceilings specified in Sections 5.3 and 5.10, above, apply — respectively.

 

The fair value of the Securities
granted to each director on the grant date, in annual terms, based on a linear calculation, shall not exceed the sum of NIS 300,000.

 

6.3.         Exercise Price — Subject to
the vesting of the options, the exercise price of the options shall be as follows:

 

		6.3.1.	With regard to options that vest subject solely due to the passing of a period
of time (without meeting targets): The exercise price shall not be less than the average price of a Company share on the Stock
Exchange in the thirty (30) trading days preceding the date of approval of the grant by the Board of Directors of the Company.
	 	 	 

		6.3.2.	With regard to options that vest subject to meeting targets: The exercise
price shall not be less than the average price of a Company share on the Stock Exchange in the thirty (30) days preceding the date
of approval of the grant by the Board of Directors of the Company.

 

It is clarified that unless
otherwise stipulated by the Compensation Committee and the Board of Directors and subject to the provisions of all laws (including
the provisions of the Companies Law-1999 (the "Companies Law") and the provisions of the Stock Exchange bylaws), the
exercise price of shares and restricted share units is zero.

 

4      For
the purpose of Section 6.3, the fair value of the Securities on the grant date in annual terms will be calculated as the amount
received from the distribution of the economic value that will be used for financial reporting purposes, by the number of years
until they vest (as opposed to the manner in which accounting expenses are recorded, which may be different because of a different
spread (over the course of years) of the economic value).

 

 

    49

     

    

 

6.4.         Formulation of Eligibility —
The Company shall be entitled to grant officers Securities that will vest after the passing of a period of time as stipulated
and subject to continued employment in the Company and shall be entitled to grant officers Securities whose vesting is
conditioned on meeting targets and/or milestones and/or upon the occurrence of a particular event that shall be established
in advance and subject to continuous continued employment (or provision of services) in the Company and/or in a related
company. Without derogating from the generality of the above, such targets may include a target share price or company value
on the exchange on which the Company's shares are traded.

 

6.5.
        The vesting period of the Securities will be as determined by the Company on the date they are granted, but in any case (other
than as described in Section 6.7, below), the vesting period of the first portion of Securities that is granted in the framework
of any grant shall not be less than one year from the grant date or from the start of the officer's employment with the Company,
as determined by the Board of Directors of the Company.

 

6.6.     Acceleration of Vesting of Securities

 

The Compensation Committee and
the Board of Directors will be entitled to stipulate that on the occurrence of an Acceleration Event (as defined, below), or as
a result of the end of an engagement because of death or disability, the vesting of the Securities granted to the officer, in whole
or in part, will accelerate, including in relation to Securities granted prior to approval of this Compensation Policy.

 

"Acceleration
Event" means one or more of the following events, when the Company has exclusive discretion to decide in relation to
each grant of Securities, which of the below events will be included under the definition of an Acceleration Event in relation
to that same grant (and provided that the definition will include at least one event from the below list): (A) Change in control
(as this term is defined in the Securities Law of 1968) in the Company; (B)
sale of all or most of the Company's assets; (C) a grant of a worldwide, exclusive license to all or most of the Company's intellectual
property; (D) a merger, after which those who were shareholders in the Company prior to the merger will hold less than 50% (or
any lower percentage determined by the Compensation Committee and the Board of Directors) of the issued equity and voting rights
in the surviving or acquiring corporation, as applicable, after the merger; (D) an initial public offering (IPO) in the US.

 

 

    50

     

    

 

6.7.         Adjustments
 — The Securities' prices will be subject to common adjustments, including adjustments with respect to a dividend,
beneficial shares, changes in equity (consolidation, split, etc.), the issuing of rights, and a change in the Company's
structure (such as: split, merger, etc.) and so forth.

 

6.8.         Method
of Exercise of the Options the Compensation Committee and the Board of Directors of the Company will be entitled to
stipulate in the framework of granting Securities, that their exercise will be made according to the value of the benefit
inherent therein ("Net Exercise"), in consideration for sale of shares, or in any other lawful method..

 

6.9.         End of
Employment Relationship —The Company's equity compensation plans will include reference to the terms that will apply in
the event of the end of the employment relationship between the officer and the Company, including in the event of the end of
the employment relationship as a result of termination, or as a result of death or disability of the officer (heaven
forfend).

 

6.10.
       Maximum Rate of Dilution — The total quantity of Securities that shall be allocated to employees of the Company during the
course of the period starting on the date of approval of this Compensation Policy and until approval of a new Compensation Policy
(hereinafter in this Section: the "Relevant Period") shall not exceed 15% of the Company's issued and paid up
equity fully diluted during the course of the Relevant Period. To the extent that when making the above calculation, there are
Securities that have already been exercised prior to the calculation date, then in relation to Securities that were thus exercised
according to the value of the benefit inherent in them (meaning, a Cash Less [sic]
exercise as stated in Section 6.10, above), the quantity of exercise shares actually allocated with respect thereto shall
be taken into account and not the quantity of convertible Securities prior to being exercised.

 

 

    51

     

    

 

6.11.      The Compensation Committee and the Board of Directors of the Company weighed the possibility of establishing a ceiling for the exercise value of variable equity components and decided not to establish such a ceiling in the framework of the Compensation Policy.

 

7.     Employment as a Contractor or by Means of a Management Company

 

The Company is entitled to
employ the officer as an independent contractor and not as a salaried employee. In such case, all of the ceilings stipulated in
this document will be translated to employer cost terms in order to examine whether the terms of the employment of that same officer
meet the principles of this Compensation Policy, which shall apply to him mutatis mutandis. In such case, the term "employment
agreement" in this policy shall be called an "agreement for the provision of services" or a "consulting agreement,"
as applicable.

 

8.     Work Overseas

 

Notwithstanding the provisions
of this Compensation Policy, the cap (including fix components and variable components) for the compensation of an officer living
outside of Israel for the purpose of performing his duties overseas shall be according to the compensation common for similar functionaries
in the Company or functionaries in other publicly traded companies similar in size and character to the Company and who live in
that same state.

 

 

    52

     

    

 

9.       Release,
Indemnification, and Insurance

 

9.1.  The
Company shall be entitled to grant officers (including directors) (a) a release from liability, in advance and retroactively,
provided that such release shall not apply to decisions or transactions in which a controlling shareholder or any officer
(including a director) has a Personal Interest, as defined in the Companies Law, including a Personal Interest of any officer
(including a director) who is not the recipient of said release; (b) liability insurance (including a Run-Off type insurance
policy); as well as (c) an undertaking to indemnify, as is Company practice, all subject to the provisions of the Companies
Law and the Company's Articles of Association.

 

9.2.  Without derogating from the
generality of the above, the Company shall be entitled, at any time during the course of the duration of this Compensation
Policy, to acquire a directors' and officers' (including controlling shareholders) liability insurance policy, as they may
serve the Company from time to time, to extend and/or to renew the existing insurance policy, and/or to enter into a new
policy on the renewal date or during the insurance coverage period, with the same insurer or with another insurer in Israel
or overseas, according to the terms specified below, for directors' and/or officers' insurance, provided that said
engagements shall be on the basis of the principles of the terms specified below and the Compensation Committee and the Board
of Directors of the Company approved it:

 

		9.2.1.	The maximum coverage level under the policy shall not exceed US $50 million
per claim, and cumulatively, for the coverage period or US $100 million per claim, and cumulatively, for the coverage period, in
the event that the Company's valuation is between US $150 million and US $500 million;
	 	9.2.2.	 
	 	 	The annual insurance premium shall not exceed the sum of (a) US
$150,000 or (b) if and as long as the Company is subject to reporting requirements of the US securities authority (the "SEC"),
the annual premium shall not exceed US $600,000. The aforementioned annual premium cap may be updated every year in up to %10
compared to the annual premium of the preceding year;
	 	 	 
	 	9.2.3.	The Compensation Committee and Board of Directors of the Company will approve annually the Company's engagement in a new policy
that meets the terms established in subsections 9.2.1 and 9.2.2, above;
	 	 	 
	 	9.2.4.	The insurance policy shall be
extended to cover lawsuits that shall be filed against the Company itself (as opposed to lawsuits against directors and/or
officers therein) relating to violation of securities laws, at least in Israel (entity coverage for securities claims) and
payment arrangement shall be established for insurance proceeds according to which the right of the directors and/or officers
to receive indemnification from the insurer under the policy takes precedence over the Company's right;
	 	 	 
	 	9.2.5.	The policy shall also cover
the liability of directors and officers considered controlling shareholders in the Company or their relatives, from time to
time, provided that the coverage terms with respect to them shall not exceed those of the other directors and/or officers in
the group.

 

 

    53

     

    

 

10.    
Reimbursement to the Company of Sums Granted to Officers

 

In the event in which the
Company's audited and consolidated financial statements are amended for any year, in such manner that had the amount of the grant,
which was due to the officer with respect to that same year, been calculated according to the amended data, the officer would have
received a grant in a different amount, the Company shall pay the officer, or the officer shall reimburse the Company, as applicable,
the difference between the amount of the grant received and that to which he would have been entitled as a result of said amendment,
provided that a period of three (3) years has not passed from the date on which the grant whose reimbursement is sought was made.
The manner of payment or reimbursement of such sums, as applicable, including spreading such sums into incremental payments, payment
dates, linkage of such sums, etc., shall be determined by the Compensation Committee and Board of Directors of the Company.

 

11.    
Term of the Compensation Policy

 

The Compensation Policy shall
remain in effect for a period of three years, commencing on the date of approval of the Compensation Policy by the general meeting.

 

12.      
Ratio Between Cost of Terms of Service and Employment of Officers and Other Company Employees

 

The Compensation Committee
and the Board of Directors of the Company examined the ratios between the cost of the terms of service and employment of the officers
and the cost5 of salary of the rest of the employees of the Company and contractors employed by the Company,6
and in particular — the ratios to the average salary and the median salary of such employees, as of the date of the approval
of this Compensation Policy, and determined that these ratios are not expected to have an impact on the employment relationships
in the Company with regard, inter alia, to the manner of the Company's activities and its size as well as the responsibility
borne by the various officers in the Company and the complexity of their positions.

 

 

 

    54

     

    

 

13.        
Miscellaneous

 

13.1.       This document does
not establish any right to remuneration of any type or class whatsoever for officers to whom this Compensation Policy applies
and/or to any other third party.

 

13.2.       It
is clarified that nothing stated in this policy shall derogate from the provisions of the Companies Law and/or the Company's Articles
of Association with regard to the manner in which the Company engages an officer of any kind in connection with the terms of their
[sic] service and employment and the provisions of this policy likewise do not derogate from any requirement to report
officers' compensation in accordance with the Securities Law, 1968 and the regulations enacted thereunder.

 

13.3.
      The Compensation Committee and Board of Directors of the Company will determine the indices comprising the variable compensation
targets in consideration of the recommendation of the Company's management.

 

13.4.       During
the process of approval of any annual plan, with all of the various components, by the Board of Directors, there will be an
annual examination of changes to the Company's targets, market conditions, the condition of the Company, etc. Accordingly,
and to the extent relevant, the targets of any plan, its indices, and its compensation targets, will be re-examined yearly,
and their actual implementation will be subject to change according to the decisions of the Board of Directors from time to
time.

 

13.5.       The
Board of Directors is entitled, after approval of a particular annual compensation plan, to resolve that compensation will
not be paid according to the plan, and is likewise entitled to order the cancellation or suspension of part or all of the
plan, based on grounds as seen fit by the Board of Directors and based on considerations of the Company's welfare.

 

13.6.       The
Board of Directors will examine from time to time the Compensation Policy and the need to adjust it if there is a substantive
change to the circumstances which existed upon its establishment or for other reasons.

 

* * * * *

 

5    "Salary Cost" — as
defined in the First Supplement A to the Companies Law.

 

6       In
calculating said ratio, only employees of Itamar Medical Ltd. were included.

 

 

 

    55Exhibit 10.13

 

 

In compliance with Regulation S-K Item 601(b)(10)(iv), certain
identified information has been excluded from this exhibit because it is both not material and would likely cause competitive harm
to the registrant if publicly disclosed CONTRACT NO. 5881 MASTER PRODUCTS AND SERVICES AGREEMENT This MASTER PRODUCTS AND SERVICES
AGREEMENT ("Agreement") is made and entered into as of this 1st day of April 2019 (the "Effective Date") by
and between KAISER FOUNDATION HEALTH PLAN, INC. ("Kaiser") and ltamar Medical Inc. ("Supplier"). This Agreement
commences on the Effective Date and expires on March 315 \ 2022,unless terminated or extended as provided herein (the "Term").
Kaiser and Supplier agree as follows: 1. DEFINITIONS 1.1 "Acceptance" means a Customer' s verification that the Product
and/or Service conforms to the Specifications,is ready for commercial use and all required documentation has been delivered. 1.2
 "Customer" means any KP Entity purchasing Products under this Agreement. 1.3 "Change Noti ce" means a document
issued by a Customer and accepted by Supplier pursuant to this Agreement to amend a Purchase Order placed by such Customer. 1.4
 "Claims" has the meaning in Section 6.7 of this Agreement. 1.5 "Delivery Location" means the location specified
by the Customer for delivery of a Product. 1.6 "Indemnified Party" has the meaning in Section 6.7 of this Agreement.
1.7 "KP Entity" means an entity participating in the integrated health care delivery organization doing business as Kaiser
Permanente® and its affiliates,which includes, without limitation, Kaiser Foundation Health Plan, Inc., Kaiser Foundation Hospitals,
The Permanente Federation, the Permanente Medical Groups, Kaiser Permanente Insurance Company,Kaiser Permanente Ventures, and all
subsidiaries and successors of the foregoing. 1.8 "Law" means federal, state and local statutes, implementing regulations,
executive orders, ordinances and case law,including healthcare program statutes,regulations and policies and local and foreign
laws and regulations applicable to Supplier and its affiliates. 1.9 "Product" means any product listed on Exhibit A that
Supplier is offering to supply under this Agreement, including related documentation, deliverables, software, spare parts and upgrades,
as applicable. 1.10 A. "Prices" means the prices for Products and Services under this Agreement as set forth in Exhibit
1.11 "Purchase Order" or "PO" means a purchase order for Products and Services issued by a Customer to Supplier
under this Agreement. Master Products and Service Agreement Template Version - 4/26/17 (#322939 v17) 1 March 20,2019 CONFIDENTIAL

  

     

     

    

 

 

DocuSign Envelope ID: 401D7E57-BECF-4F17-A613-8D2D118C4753 1.12
 “Specifications” means the technical and functional specifications for a Product and Services as described in Exhibit
B or, if no specifications are set forth in Exhibit B, the published specifications. 2. ORGANIZATION AND BACKGROUND 2.1 Supplier.
During the Term of this Agreement, Supplier agrees to supply the Products and Services to KP Entities according to the terms and
conditions as set forth in this Agreement. 2.2 Customers. Any KP Entity (including any entity that becomes a KP Entity after the
Effective Date) in any location within the United States may elect to purchase Products and Services pursuant to the terms and
conditions of this Agreement. This Agreement does not obligate any KP Entity to purchase any minimum quantity or dollar value of
Products or Services. This Agreement is non-exclusive. KP Entities may purchase competing products or services from other vendors
without restriction. A Customer is bound to the terms and conditions of this Agreement by purchasing Products or Services under
this Agreement. Each Customer is solely and exclusively liable directly to Supplier for all of its payments and any other obligations
with respect to the Products and Services purchased and Purchase Orders placed by such Customer. 2.3 Kaiser. Kaiser has negotiated
this Agreement for the benefit of the KP Entities. Kaiser does not commit to any participation by KP Entities. If Kaiser places
Purchase Orders, it will be deemed to be a KP Entity and will have all of the rights and obligations of a Customer under this Agreement
with respect to its Purchase Orders. Kaiser has no liability or responsibility to Supplier for a Purchase Order placed by any other
KP Entity. 3. PURCHASING PRODUCTS [REDACTED] 3.1 Pricing. Exhibit A sets forth the Prices for each Product and Service. Within
30 days of Kaiser’s or any Customer’s determination that Supplier is not in compliance, Supplier must amend Exhibit
A of this Agreement to provide the more favorable terms. Rebate. Supplier will issue a credit to Kaiser for the period of April
1st through March 31st of the 3.2 following year (the "Rebate Period"), during each year of the Agreement, based on the
incremental increase of the annual aggregate spend under the Agreement from the previous contract year with [REDACTED] Supplier.
The rebate value will correspond to of the incremental increase in value of spend during the Rebate Period under the Agreement.
Customers may use this credit in exchange for any of the following – consumables, products and upgrades sold by Supplier,
at the Agreement prices. For example: [REDACTED] if the annual aggregate spend with Supplier under the Agreement in 2017 Supplier
will provide the credit amount to KP within 30 days after the end of the Rebate Period. The rebate will be allocated to the purchasing
Customers based on Kaiser's written instructions to Supplier. 3.3 Taxes. Master Products and Service Agreement Template Version
 – 4/26/17 [#322939-v17] 2 March 20, 2019 CONFIDENTIAL

 

     

     

    

 

  

DocuSign Envelope ID: 401D7E57-BECF-4F17-A613-8D2D118C4753 3.3.1
Taxes on Direct Purchases. Supplier must, as applicable, calculate and pay any applicable local and state sales/use tax with respect
to the direct purchase of any Product and Service. Unless the applicable Customer is tax-exempt, Supplier may invoice the Customer
for these taxes if they are correctly and separately reflected on the invoice. Should the Supplier not be required to collect sales
taxes on a taxable transaction, Customer will self-assess use taxes on the transaction and remit such taxes directly to the proper
tax authorities and will provide verification of the amount paid upon request by the Supplier. 3.3.2 Property Taxes. The party
with title to a Product must pay any property tax. Supplier must reimburse any Customer for property tax the Customer pays on a
Product owned by Supplier. 3.3.3 Federal Excise Tax. Supplier must pay any Federal Excise Tax. Supplier may invoice the Customer
for these taxes if (a) it is required by law; and (b) they are correctly and separately reflected on the invoice. 3.4 Ordering.
Customer may issue a Purchase Order using Customer’s designated format (e.g. fax, electronic or web-based interface). Customer
may change a Purchase Order prior to the shipment date by issuing a Change Notice. Customer is not required to place any minimum
orders for Products or Services or pay any minimum fees in connection with a Purchase Order or Change Notice. 3.5 Shipment. Unless
otherwise agreed to between Supplier and any Customer, Supplier must ship an ordered Product to the Delivery Location within two
business days after Supplier’s receipt of the Customer’s order for the Product. All Products must be properly packed.
Customer’s prior written approval is required for any partial shipments. Shipping terms are as follows: (i) Products Excluding
Capital Equipment - FOB Origin, Freight Collect. Except as set forth below, prices for Products are FOB Origin, Freight Collect,
with risk of loss passing to Customer upon delivery to Customer's common carrier. Supplier shall arrange shipment of the Product
(including any expedited or overnight shipment) using the carrier, shipping and billing information provided by Customer, as stated
in Chapter 5 (Transportation) of the Distribution and Transportation Guide referenced in Exhibit B of this Agreement; Capital Equipment
- FOB Destination. Prices for capital equipment Products, which are (ii) [REDACTED] individually priced at or more (“Capital
Equipment”), are FOB Destination, with risk of loss passing to Customer upon delivery to Customer. Upon Customer’s
request, Supplier will ship Capital Equipment FOB Origin, Freight Collect using the carrier and billing information provided by
Customer and with the prices for the Capital Equipment decreased to remove the freight; and Software. All software supplied to
Customer (excluding software embedded in the Products) must be delivered to Customer electronically. (iii) 3.6 Invoicing. Supplier
is solely responsible for invoicing Customer for Products and Services. Supplier will not invoice Customer for any fees or expenses
not specified in this Agreement or a PO, unless mutually agreed upon in writing between Supplier and Customer. Supplier’s
invoices must comply with the Kaiser Permanente Invoice and Accounts Payable Requirements, which are referenced in Exhibit B. Unless
otherwise agreed in Exhibit A, Supplier will not issue an invoice for Products and related Services until (i) the Acceptance date
or (ii) the shipment date, if Acceptance is not applicable. Master Products and Service Agreement Template Version – 4/26/17
[#322939-v17] 3 March 20, 2019 CONFIDENTIAL

 

     

     

    

 

 

DocuSign Envelope ID: 401D7E57-BECF-4F17-A613-8D2D118C4753 Payment.
A Customer must pay for an ordered Product within[REDACTED] after the Customer’s 3.7 receipt of an accurate invoice. Supplier
will not place Kaiser or any Customer’s facilities or locations on credit hold for any reason. All amounts that a Customer
is required to pay to Supplier under this Agreement will be subject to deduction or offset by Customer from any amounts owed by
Supplier to Customer by reason of any claim or counterclaim arising out of this Agreement or any Purchase order. 3.8 Products.
3.8.1 Packaging. All Product packaging and shipping containers should identify the Purchase Order number, UPC barcodes, expiration
date and other Product identifiers reasonably required by Kaiser or a Customer. All shipments must include a packing slip. 3.8.2
Discontinuing Products. Unless otherwise agreed, Supplier will not (i) discontinue the supply of any Product without 12 months’
prior written notice to Kaiser or (ii) discontinue the supply of maintenance services or spare parts for Products, if any, during
the useful life of the Products. 3.8.3 Support and Maintenance. Supplier agrees to make service and maintenance support available
for its Products throughout the useful life of the Product supplied to Kaiser and for a minimum of seven (7) years after the sale
of a Product. 3.8.4 Software License. To the extent a Product includes software, Supplier hereby grants to Customer, for the benefit
of the KP Entities, a non-exclusive, worldwide, perpetual and unlimited (unless a limitation on the number of users, computer systems
or other similar restrictions on Customer’s usage is expressly stated in Exhibit A) license to install, display, access,
store and use any software and documentation supplied by Supplier to Customer under the Agreement (including any updates or modifications
thereof) for the Customer’s business purposes. This license grant includes, at no additional charge, the right to make and
use a reasonable number of copies of the software and documentation for testing, back-up, archival and disaster recovery purposes,
and of the documentation for internal training, support and deployment. Customer may permit its consultants and contractors to
exercise its rights under this license for the purpose of providing services to Customer. 4. WARRANTIES 4.1 General. Supplier represents
and warrants that (a) Products will be free from defects in design, workmanship and materials and will conform to the applicable
Specifications for 12 months from the date of Acceptance; and (b) Supplier’s employees and agents will have the certifications,
skills and qualifications necessary to provide the Services in a timely, competent, and professional manner in accordance with
Law and generally accepted industry standards. Supplier also warrants that consumable Products will have a minimum 12 month expiration
date/shelf life on the shipment date. 4.2 Title. Supplier warrants that it has good and merchantable title to the Products, and
the Products must be delivered to Customer free and clear of all liens and encumbrances. 4.3 Extension of Warranties. Supplier’s
warranties provided in this Section and as otherwise provided in this Agreement will run to and extend to a Customer and its successors,
assigns, customers and users of Products and to any other person or entity to whom Products are transferred. Master Products and
Service Agreement Template Version – 4/26/17 [#322939-v17] 4 March 20, 2019 CONFIDENTIAL

 

     

     

    

 

 

 

DocuSign Envelope ID: 401D7E57-BECF-4F17-A613-8D2D118C4753 4.4
Warranties Cumulative. The warranties provided in this Section and all other warranties provided under this Agreement are cumulative
and will apply to any replacement or modification of Products by Supplier and such warranties are in addition to any warranties
provided by law or in equity. 4.5 Product Returns. If Products or Services are nonconforming to the Agreement or PO, Customer may,
at its option, return any or all of the Products at Supplier’s expense for a full refund or require Supplier to promptly
replace, repair or re-perform non-conforming Products and/or Services without any penalty, termination or cancellation fees. Customer
has 45 days from the date of delivery to inspect and accept or reject the Product. Upon the expiration of said 45 days, the Product
shall be deemed Accepted. Supplier will be responsible for Customer’s reasonable costs and expenses of collecting and transporting
rejected Products to Supplier. Failure to inspect and test by a Customer will not relieve Supplier in any way from its obligations
under this Agreement, including any testing, inspection, warranty and quality control responsibilities. 4.6 Product Recalls. In
addition to any notification required by Law, within 24 hours after Supplier first learns of a recall or other circumstance where
a Product may present an unreasonable risk of substantial harm, Supplier agrees to notify the Kaiser Permanente National Recall
Department (kp-product-recall@kp.org) and any Customer facility that received or ordered the affected Product. Supplier must use
its reasonable commercial efforts to monitor the recall status of affected Products. Each notice must include specific information
related to the recall as well as the suggested action to be taken by the Customer. Supplier must reimburse each Customer for its
costs associated with the correction of a recall and actions taken in response to a recall. This Section survives the expiration
or other termination of this Agreement, regardless of the cause giving rise to the expiration or termination. 4.7 Disclaimer. SUPPLIER
DISCLAIMS ALL OTHER REPRESENTATIONS AND WARRANTIES, EITHER EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY
AND FITNESS FOR A PARTICULAR PURPOSE. EXCEPT WITH RESPECT TO SUPPLIER’S PRODUCT RECALL AND INDEMNITY OBLIGATIONS UNDER THIS
AGREEMENT, ANY STATEMENT OF WORK AND ANY ASSOCIATED BUSINESS ASSOCIATE AGREEMENT, IN NO EVENT WILL SUPPLIER OR CUSTOMER BE LIABLE
FOR ANY SPECIAL, PUNITIVE, INDIRECT OR CONSEQUENTIAL LOSSES OR DAMAGES ARISING HEREUNDER, INCLUDING BUT NOT LIMITED TO LOST PROFITS,
BUSINESS INTERRUPTION LOSSES OR LOSS OF GOODWILL, EVEN IF SUPPLIER OR KAISER OR CUSTOMER HAVE BEEN ADVISED OF THE POSSIBILITY OF
SUCH POTENTIAL LOSS OR DAMAGE. 5. TERM AND TERMINATION 5.1 Extension of Term. Kaiser may extend the Term of this Agreement for
two (2) additional one (1) year periods. Kaiser will provide written notice of the extension of the Term prior to the expiration
of the then-current Term. 5.2 Termination for Convenience. Kaiser may terminate this Agreement at any time with or without cause
upon 60 days prior written notice to Supplier. 5.3 Termination for Breach. This Agreement and any Purchase Orders may be terminated
without cost by sending written notice to the breaching party if a material breach has not been cured within thirty (30) days after
receipt of written notice describing such breach in reasonable detail. 5.4Effect of Termination. The termination of this Agreement
for any reason does not excuse either party from performing any duty or obligation assumed under this Agreement before the date
of Master Products and Service Agreement Template Version – 4/26/17 [#322939-v17] 5 March 20, 2019 CONFIDENTIAL

 

     

     

    

 

 

 

DocuSign Envelope ID: 401D7E57-BECF-4F17-A613-8D2D118C4753 termination.
The termination of this Agreement or a Purchase Order (or Change Notice) for material breach (i) does not have the effect of waiving
any right the non-breaching party may have to obtain performance, and (ii) does not preclude the non-breaching party from pursuing
any and all remedies available to it at law or equity. Upon termination of any Purchase Order (or Change Notice) by Customer for
material breach, Customer will not be obligated to make any payments due on or after the effective date of termination, if any,
and will be entitled to a pro-rata refund of any prepayments. 6. GENERAL PROVISIONS 6.1. Accounting Reports. If requested by Kaiser,
following the end of each calendar quarter, Supplier must submit to Customer an accounts receivable statement (in electronic format,
preferred). The statement must include all open invoices, open credit memos, deductions, adjustments and cash on account/unapplied
cash for the Customer and provide, if available, purchase order numbers, transaction numbers, transaction dates and details, check
numbers, and amounts. Supplier must send the reports by U.S. mail, fax, or email to: Kaiser Permanente Health Plan Inc. Attn: Statement
Review Department, Controller's Office, 1714 Franklin Street, # 331, Oakland CA 94612, Fax No: 800.364.7095, E-Mail: statement.review@kp.org
6.2. Sales Records. If requested by Customer, Supplier must provide periodic sales reports of the number of units of each Product
and any Services distributed or sold to Customer pursuant to this Agreement in a form, content, and schedule satisfactory to the
Customer. Supplier must not (a) sell or distribute sales or usage information to anyone not a party to this Agreement without the
prior written consent of the Customer or (b) distribute copies, excerpts, facsimiles or summaries to Customer’s personnel
without the prior approval of the Customer’s personnel who originally requested the information. 6.3. Product Catalog. If
requested by Kaiser, within 30 days after the Effective Date of this Agreement, Supplier will prepare a Product/Services catalog
and deliver it to Kaiser for its approval on media reasonably requested by Kaiser. The catalog will be identified with the names
and logos of both Supplier and Kaiser (using the proper trademark information provided to Supplier by Kaiser) and will include
Product and Services descriptions, Specifications, and any other information reasonably required by Kaiser to enable KP Entities
to make informed purchasing decisions. Upon Kaiser’s approval of the catalog, Supplier will distribute catalogs to KP Entities,
with the number and distribution list specified by Kaiser from time to time. On or before the 10th day of each calendar month,
Supplier will distribute catalog updates to KP Entities, if applicable. All preparation and delivery of catalogs to KP Entities
will be at Supplier’s cost and expense. 6.4. Assistance/Training/Documentation. Prior to the shipment date of a Product and
as reasonably requested thereafter, Supplier will provide Customers with all necessary education, training, documentation and assistance
in connection with the proper installation, operation and handling of each Product or any problems therewith at no additional charge
unless otherwise specified in Exhibit A. The aforementioned training shall include the following: (a) Technical Training x x x
Replacing the PAT cable Replacing the battery Device preparation Changing the probe o Master Products and Service Agreement Template
Version – 4/26/17 [#322939-v17] 6 March 20, 2019 CONFIDENTIAL

 

     

     

    

 

 

 

DocuSign Envelope ID: 401D7E57-BECF-4F17-A613-8D2D118C4753 SBP
placement and adhesive replacement Testing the device prior to distribution o o x x Proper patient education / instruction Device
cleaning x zzzPAT software navigation Loading patient data Downloading the study Storing patient data Editing the sleep study Recalling
studies o o o o o (b) Clinical Training x Data Interpretation Understanding the patient report Evaluation of the PAT signal o o
All trainings may be conducted in person or via electronic means (such as, webinars) and will be provided by Itamar Medical Inc.
as long as the devices are in use by Kaiser. 6.5. No Disruption in Use of Products. Supplier acknowledges that Customer is a provider
of health care services; that Customer’s use of Products is vital to the business operations of Customer and to the health
and safety of Customer’s patients and members; and that any interruption of Customer’s business could result in substantial
liability to Customer. Supplier warrants and represents that it will not at any time render Products unusable or inoperable, take
possession of Products provided to Customer, or in any way deliberately take any action to impede or interfere with the use or
operation of Products by Customer, or otherwise impede or interfere with Customer’s businesses. 6.6. Reservation of Security
Interest Prohibited. Supplier will not reserve a security interest in Products. Supplier will not encumber Products or impair a
Customer’s ability to obtain financing of Products. 6.7. General Indemnification. Supplier must indemnify, defend and hold
harmless Kaiser, each Customer, and each of their respective affiliates, officers, directors, employees and agents (in this Section
6.7, each an “KP Indemnified Party”) from and against any and all claims, demands, liabilities, damages, fines, costs
and expenses (including attorneys’ and expert witness fees) (in this Section 6.7, collectively, “Claims”) made
by a third party and arising from Supplier’s breach of this Agreement, any defect in a Product or the negligence/willful
misconduct of Supplier; provided however, if the foregoing indemnification is based on Supplier’s fault and there is also
fault on the part of an KP Indemnified Party, the indemnification shall be administered on a comparative fault basis. The foregoing
shall be subject to KP Indemnified Party providing prompt written notice to Supplier of any event or circumstances which may be
subject to Claims and allowing Supplier to manage the defense of any such Claims. KP Indemnified Party shall not settle any Claims,
unreasonably withheld. absent the Supplier’s prior written consent, which shall not be Master Products and Service Agreement
Template Version – 4/26/17 [#322939-v17] 7 March 20, 2019 CONFIDENTIAL

 

     

     

    

 

  

DocuSign Envelope ID: 401D7E57-BECF-4F17-A613-8D2D118C4753 Kaiser
and each pertinent Customer must indemnify, defend and hold harmless Supplier, and each of its respective affiliates, officers,
directors, employees and agents (in this Section 6.7, each an “Supplier Indemnified Party”) from and against any and
all Claims”) made by a third party and arising from Kaiser and each pertinent Customer’s (a) breach of this Agreement,
(b) any negligence/willful misconduct of Kaiser and each pertinent Customer (c) the misuse of any Products or use non-compliant
with Suppliers’ written instructions with respect to the Products; provided however, if the foregoing indemnification is
based on Kaiser and each pertinent Customer’s fault and there is also fault on the part of an Supplier Indemnified Party,
the indemnification shall be administered on a comparative fault basis. The foregoing shall be subject to Supplier Indemnified
Party providing prompt written notice to Kaiser and each pertinent Customer of any event or circumstances which may be subject
to Claims and allowing Kaiser and the pertinent Customer to manage the defense of any such Claims. Supplier Indemnified Party shall
not settle any Claims, absent Kaiser and the pertinent Customer’s prior written consent, which shall not be unreasonably
withheld. 6.8. Infringement Indemnification. Supplier will indemnify, defend, and hold each Indemnified Party harmless from and
against any Claims that a Product or Services furnished to a Customer under this Agreement infringes any patent, trademark, copyright,
or other proprietary right of any third party or becomes the subject of an injunction or settlement prohibiting the use of such
Product or Service. The foregoing shall be subject to Indemnified Party providing prompt written notice to Supplier of any event
or circumstances which may give rise to indemnification under this section and allowing Supplier to manage the defense of any related
Claims. Indemnified Party shall not settle any Claims, absent the Supplier’s prior written consent, which shall not be unreasonably
withheld. In such a case, Supplier must at its own expense and at its discretion (i) procure for each Customer the right to continue
using the Product/Service, or (ii) replace the Product with non-infringing products with equivalent or better capacity performance,
or (iii) refund to each Customer the price paid for the Product and Services. 6.9. Insurance. Supplier shall procure and maintain
the following insurance coverage (i) all insurance coverage required by federal and state law, including workers’ compensation
insurance with statutory minimum limits and employer’s liability insurance with limits of not less than [REDACTED] each claim,
(ii) current ISO commercial general liability policy, or equivalent coverage, with limits of not less than [REDACTED] per occurrence
and aggregate, including coverage for products liability and contractual liability, (iii) if Supplier is providing professional
services - professional liability (E&O) insurance with limits of at least [REDACTED] which provides coverage on an occurrence
basis, or if on a “claims made” basis, then Supplier will maintain continuous coverage for five years after termination
or expiration of the Agreement or purchase “tail coverage” for no less than five years after the policy terminates
or lapses; and (iv) automobile liability insurance with limits of not less than [REDACTED] covering use of any auto. Supplier’s
insurance must be primary and no other insurance maintained by Kaiser will be called upon to contribute to a loss. All insurance
required of Supplier shall be through insurance carriers rated “A, X” or better by A.M. Best, and contain a separation
of insureds endorsement. The commercial general liability insurance must cover Customer as an additional insured. Upon request,
Supplier will provide Kaiser with an industry-standard certificate of insurance evidencing these coverages and a revised certificate
of insurance if any of the policies are changed. If this Agreement includes Products subject to FDA oversight, of [REDACTED] ,
Supplier must also maintain an umbrella liability insurance policy in excess of the commercial general liability, employer’s
liability, and commercial automobile liability coverage. 7. MISCELLANEOUS Master Products and Service Agreement Template Version
 – 4/26/17 [#322939-v17] 8 March 20, 2019 CONFIDENTIAL

 

     

     

    

 

 

DocuSign Envelope ID: 401D7E57-BECF-4F17-A613-8D2D118C4753 7.1
Independent Contractor. Supplier is an independent contractor and engages in the operation of its own business, and neither party
is or will be considered to be the agent of the other party for any purposes. A party has no authorization to enter into any contracts,
assume any obligations or make any warranties or representations on behalf of the other party. Nothing in this Agreement will be
construed to establish a relationship of co-partner or joint venture between the parties or with any KP Entity. Kaiser or a KP
Entity will not be responsible to Supplier, the employees of Supplier or any governing body for taxes on the payroll of Supplier.
7.2 Successors and Assigns. Supplier shall not assign, transfer or delegate any of the rights or obligations under this Agreement
without the prior written consent of Kaiser. This Agreement and all of its provisions shall inure to the benefit of and become
binding upon the parties and the successors and permitted assigns of the respective parties. 7.3 Confidentiality. The provisions
of this Agreement are deemed to be confidential information and neither party will, without the other party’s prior written
consent, divulge any of the provisions set forth in this Agreement or any confidential or propriety information about Kaiser or
any KP Entity, including without limitation, information about its purchase, operations, customers and strategies, to any third
parties; provided, however, a party receiving confidential information (“receiving party”) may disclose it to a third
party having a need to know such information in order to perform the receiving party’s obligations under the terms of this
Agreement or as may otherwise be required by Law (including Supplier’s performance of its public disclosure obligations as
a publicly traded company in Israel and in the United States), but the receiving party is responsible to ensure that such third
parties keep the disclosed information confidential and that any disclosure required by Law, shall be limited to the minimum extent
required to comply with its legal obligations. 7.4 Compliance with Laws. Supplier agrees that all Products and Services provided
pursuant to this Agreement shall be in compliance with all applicable Laws, including, as applicable, the Federal anti-kickback
statute, (42 U.S.C. 1320a-7b), the STARK law (42 U.S.C. 1395nn) and the Health Insurance and Portability and Accountability Act
of 1996, as amended, and the rules and regulations promulgated under its authority (“HIPAA”). Supplier has and shall
maintain throughout the Term of this Agreement: (a) all professional and business licenses, certifications and similar requirements
as required by Law; and (b) all accrediting requirements (if applicable) to perform the Services under this Agreement. In the performance
of this Agreement Kaiser and Customer hereby represent and warrant that they shall abide by all Laws applicable to them, and that
it shall use and dispense the Products in compliance with Supplier’s instructions. 7.5 Right to Inspect. Upon five (5) days
notice from Kaiser, Supplier will provide Kaiser’s internal auditors (or such independent auditors and inspectors as Kaiser
may designate in writing and have agreed to abide by reasonable confidentiality provisions) with access and the right to make copies
of Supplier’s books and records relating to orders, invoices, sales reports and internal materials relevant to verifying
the accuracy of the invoices submitted by Supplier to Customers. Supplier will cooperate with the inspection and will make the
records and related materials reasonably required to conduct the inspection available on a timely basis. If any audit reveals any
variance from any invoice in excess of 2% of the amount shown on such invoice, Supplier will reimburse Kaiser for all reasonable
costs and expenses incurred in conducting such audit. 7.6 Kaiser Additional Requirements. Supplier will comply with the Kaiser
Additional Requirements set forth in Exhibit B. Master Products and Service Agreement Template Version – 4/26/17 [#322939-v17]
9 March 20, 2019 CONFIDENTIAL

 

     

     

    

 

 

 

DocuSign Envelope ID: 401D7E57-BECF-4F17-A613-8D2D118C4753 7.7
Governing Law. This Agreement is governed by and construed in accordance with the internal laws of the State of California, without
regard to its choice of law principles. 7.8 Notices. All notices provided under this Agreement will be in writing, and will be
deemed given upon receipt if sent as follows: personally delivered or sent by confirmed fax, overnight mail by USPS or a commercial
service with confirmed delivery, or certified mail (return receipt requested). If notice is mailed or faxed, delivery is effective
at the date and time shown on the confirmation or return receipt. The addresses for notices to Kaiser and Supplier are set forth
on the signature page of this Agreement. The address for notices to other Customers will be set forth in the Customer’s Purchase
Order unless otherwise agreed. These addresses may be changed by notice to the other party. 7.9 Publicity. Without limitation to
Section 7.3 above, Supplier will not, without the prior written consent of Kaiser, use in advertising, publicity, on the internet
or otherwise the names, trade names, service marks, trade dress or logo of Kaiser, KP Entities, the Kaiser Permanente Medical Care
Program or any affiliates of these entities or refer to the existence of this Agreement in any press releases, advertising, web
sites or materials distributed or made available to prospective customers or other third parties. Any internal designation by Kaiser
of Supplier’s Product as a ‘preferred product’ or a Customer’s purchase of Products or Services will not
constitute an endorsement of Supplier’s Products or Services by Kaiser or KP Entities. 7.10 No Waiver. The waiver of any
breach of any term or condition of this Agreement does not waive any other breach of that term or condition or of any other term
or condition, unless agreed to in writing signed by both parties. 7.11 Severability. If any part of this Agreement is for any reason
found to be unenforceable, then the unenforceable provision is reformed to conform to the law, and all other parts of this Agreement
nevertheless remain enforceable. 7.12 Headings. The descriptive headings of the sections of this Agreement are inserted for convenience
only and do not control or affect the meaning or construction of any section. 7.13 Remedies Cumulative. The rights and remedies
of Kaiser and each KP Entity provided in this Agreement are not exclusive and are in addition to any other rights and remedies
provided by law, including the California Uniform Commercial Code. 7.14 Time is of the Essence. Time is of the essence for any
act or obligation of either party under this Agreement when time is a factor. 7.15 Force Majeure. Neither Party will be liable
for any delays resulting from circumstances or causes beyond its reasonable control, including, without limitation, fire or other
casualty, act of God, war or other violence, or any Law, of any governmental agency or authority (“Force Majeure”)
if the Party claiming the Force Majeure uses reasonable efforts to continue to perform and give prompt written notice to the other
party; provided, however, a Force Majeure does not excuse a party from fulfilling its obligations under an agreed business continuity
plan. In the event any Force Majeure will continue or reasonably be expected to continue for more than 30 days, the party not claiming
a Force Majeure is entitled to immediately terminate this Agreement by written notice to the other party. Master Products and Service
Agreement Template Version – 4/26/17 [#322939-v17] 10 March 20, 2019 CONFIDENTIAL

 

     

     

    

 

 

DocuSign Envelope ID: 401D7E57-BECF-4F17-A613-8D2D118C4753 7.16
Survival. Any provision of this Agreement which by its nature must survive termination or expiration in order to achieve the fundamental
purposes of this Agreement will survive any termination or expiration of this Agreement. 7.17 Controlling Terms. The provisions
of this Agreement and the terms of any Purchase Order or Change Notice will supersede any inconsistent provisions contained in
Supplier’s quotation, invoice, confirmation, acceptance, acknowledgement or similar form. All terms or conditions proposed
in Supplier’s acceptance or acknowledgment form which add to, vary from, or conflict with the provision in this Agreement
will be void. Any pre-printed terms in Customer’s or Supplier’s documents will also be void. In the event of conflicting
provisions between the following documents, the provisions will govern in the following order: the latest Change Notice, the Purchase
Order, the main body of this Agreement; and the other exhibits in order of priority as set forth in the table following the signature
blocks. To the extent the terms of this Agreement directly conflict with the terms of a Business Associate Agreement which is incorporated
into this Agreement, the terms of the Business Associate Agreement will take precedence. 7.18 Entire Agreement. This Agreement
(which includes the Exhibits and Business Associate Agreement (if applicable)) may be executed in any number of counterparts, each
of which is deemed an original but all of which constitute the same instrument. This Agreement may be executed by the exchange
of faxed executed copies, certified electronic signatures, or copies delivered by electronic mail in Adobe PDF or similar format,
and any signature transmitted by such means for the purpose of executing this Agreement shall be deemed an original signature for
purposes of this Agreement. This Agreement, including all exhibits, attachments and documents incorporated herein by reference,
constitutes the entire agreement on this subject and supersedes all previous and contemporaneous communications, representations,
or agreements between Kaiser and Supplier regarding the referenced subject matter. This Agreement may not be modified orally, and
no modification, amendment, or supplement is binding unless it is in writing and signed by authorized representatives of Kaiser
and Supplier. Master Products and Service Agreement Template Version – 4/26/17 [#322939-v17] 11 March 20, 2019 CONFIDENTIAL

 

     

     

    

 

 

 

DocuSign Envelope 10: 40107E57-BECF-4F17-A613-8020118C4753 IN
WITNESS WHEREOF,Kaiser and Supplier have executed this Agreement as written below. SUPPLIFR: KAISER FOUNnATION HFAITH PIAN,INC.
lrDocuSigned by: :L E7!?:1& ITAMA {;j"ti By: L By:_ Title:_ T"tl 79CBE84B704246E... VP sourcing 1 e._ CEO ------------Print
Name:_ Date:_ G1i ad_G.:;.1.:..1..:...c.;:..:.k;:..._ _ Print Name:_ Date:_ carlos A Agu1i ar 04/22/!::..:20::..::::..::::9 _ 04/02/2
0:.:..::::9 _ Address and Contact Person for Notices: Shy Sasson,Chief Financial Officer 3290 Cumberland Club Drive,Suite 100 Atlanta,GA
30339 Fax: 888 742-2628 Address and Contact Person for Notices: VP of Sourcing Kaiser Foundation Health Plan,Inc. 1800 Harrison
Street,Suite 1800 Oakland,CA 94612 Fax: (510) 625-2882 Master Products and Service Agreement Template Version - 4/26/17 (#322939-v17)
12 March 20, 2019 CONFIDENTIAL Agreement Reference Title Order of Priority Body of Agreement 1 Exhibit A Products and Pricing 2
Exhibit B Additional Requirements 3

 

     

     

    

 

 

DocuSign Envelope 10: 40107E57-BECF-4F17-A613-8020118C4753 EXHIBIT
A Products and Pricing Purchase Price Manufacturer Catalog# Conversion Factor Description [REDACTED] AC0000033 AC2000110 AC2000300
AC2000400 AC2100210 AC2101200 AC2110502 AC3000100 AC3000300 AS0037055 AS0060500 A$0060520 A$0060590 AS0060600 AS0060620 AS0065511
AS0065515 AS1680026 AS2151301 AS2151500 AS2151600 AS2161541 AS2165200 AS2165205 CB1000012 CP7200010 CS1000101 CS2110500 CT0070000
FG2110010 FG2110015 FG2110030 FG2110060 FG2111510 FG2111515 FG2111520 FG2111530 FG2111540 FG2111550 FG2111560 FG2170102 MP2173300
MP2173302 WatchPAT200/U Docking Station Adhesive Set for SBP Sensor 24 Bracelets for WatchPAT SBP Sensor for WatchPAT 12 Pneumo-Opt
sip Probes 12 Pneumo-Opt uPAT Probes Watch-PAT200U Central Plus Sensor Replacement US & ROW CentralPlus Add-On Kit with RESBP
US & ROW li-lon Polymer Battery Pack PAT Cable WP200 Unified Oximeter sensor for WP200 PAT Cable WP200 PAT Cable WP200 Oximeter
sensor for WP200 Cable Bracelet to WP200 Cable Bracelet to WatchPAT200U Endo-PAT2000 S/W CD v3.6.2 Strap assy Watch-PAT200 Strap
for Watch-PAT200U Small Strap for Watch-PAT200U ZzzPAT S/W CD V=4.6.71.7 Watch-PAT200 Patient Video WatchPAT SBS CD Cord USB A/Mini
- B Oximeter adhesive bands x 25 1Year Warranty Watch-PAT WP200U With Trade In Bracelet Clips WatchPAT 200 Kit,10 Bundle WatchPAT
200 Kit,15 Bundle WatchPAT 200 Kit,30 Bundle WatchPAT 200 Kit, 60 Bundle WatchPAT 200 Kit,10 Central Bundle WatchPAT 200 Kit,15
Central Bundle WatchPAT 200 Kit, 20 Central Bundle WatchPAT 200 Kit,30 Central Bundle WatchPAT 200 Kit, 40 Central Bundle WatchPAT
200 Kit,50 Central Bundle WatchPAT 200 Kit, 60 Central Bundle Sleeve Disposable x25 Insert for WP200 Carry Case Carrying Case WP200
1 12 24 1 12 12 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25 1 1 6 1 1 1 1 1 1 1 1 1 1 1 25 1 1 Ea Ca Ca Ea Ca Ca Ea Ea Ea Ea Ea Ea
Ea Ea Ea Ea Ea Ea Ea Ea Ea Ea Ea Ea Ea Ca Ea Ea Ca Ea Ea Ea Ea Ea Ea Ea Ea Ea Ea Ea Ea Ea Ea 1Ea/Ea 12Ea/Ca 24Ea/Ca 1Ea/Ea 12Ea/Ca
12Ea/Ca 1Ea/Ea 1Ea/Ea 1Ea/Ea 1Ea/Ea 1Ea/Ea 1Ea/Ea 1Ea/Ea 1Ea/Ea 1Ea/Ea 1Ea/Ea 1Ea/Ea 1Ea/Ea 1Ea/Ea 1Ea/Ea 1Ea/Ea 1Ea/Ea 1Ea/Ea
1Ea/Ea 1Ea/Ea 25Ea/Ca 1Ea/Ea 1Ea/Ea 6Ea/Ca 1Ea/Ea 1Ea/Ea 1Ea/Ea 1Ea/Ea 1Ea/Ea 1Ea/Ea 1Ea/Ea 1Ea/Ea 1Ea/Ea 1Ea/Ea 1Ea/Ea 25Ea/Ca
1Ea/Ea 1Ea/Ea [REDACTED) [REDACTED] .[REDACTED) [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED) [REDACTED]
[REDACTED) [REDACTED) [REDAC1ED] [REDACTED] [REDACTED) [REDACTED) [REDACTED] [REDACTED) [REDACTED) (JJ!DJ\Ct!D) [JJ!DACtm: [REDACTED)
(REDACTED) [REDACTED) [REDAC1ED] [REDACTED] [REDACTED) [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED]) [REDACTED]
[REDACTED] [REDACTED] :[REDACTED] [REDACTED] [REDAC1ED) [REDACTED) [REDAC1ED] Master Products and Service Agreement Template Version
- 4/26/17 (#322939-v17) 13 March 20,2019 CONFIDENTIAL

 

     

     

    

 

 

 

DocuSign Envelope 10: 40107E57-BECF-4F17-A613-8020118C4753 (RED
ACTED) MP2173310 MP2272130 MP2272135 OM2193301 OM2193302 OM2193303 OM2193304 om2193305 OM2193306 OM2193307 OM2193308 OM2193313
OM2193319 OM2193320 OM2193332 OM2193333 OM2193334 OM2193339 Small Carrying Case WP200 Battery cover for WatchPAT200 Battery cover
for WatchPAT200 New Step by Step Guide WP200 Swedish Step by Step Guide WP200 Hebrew Step by Step Guide WP200 for Bracelet Step
by Step Guide WP200 Russian Step by Step Guide WP200 Spanish Step by Step Guide WP200 Arabic Step by Step Guide WP200 Chinese Step
by Step Guide WP200 English Step By Step Guide Spanish Step By Step Guide Arabic Step by Step Guide French Step By Step Guide Russian
Step By Step Guide Span WP200 Unified+ltamar SBP Step By Step Guide ROW WP200 Unified+ltamar SBP StepByStep Guide Arabic Step By
Step Guide Spanish EU WP200 Unified+ltamar SBP Step By Step Guide - English Kaiser Step By Step Guide -Spanish Kaiser Step By Step
Guide Spanish US WP200 Unified+ltamar SBP Quick Reference Cards for WP200 Step By Step Guide US and Canada WP200 Unified+ltamar
SBP Quick Reference Cards for WP200+SBP New Quick Reference Cards for WP200+SBP New Operation ManualWP200 Operation ManualWP200+SBP
New Operation Manual Pow-Supp.100-240VAC W.M. Watch-PAT200 Demo Device Upgrade Kit Watch-PAT200U Oximeter sensor for WP200 PAT
Cable WP200 Oximeter sensor for WP200 Nonin Adapter Box Assy Nonin Adapter Box Assy Nonin Adapter Box Assy 1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 Ea Ea Ea Ea Ea Ea Ea Ea Ea Ea Ea Ea Ea Ea Ea Ea Ea Ea 1Ea/Ea 1Ea/Ea 1Ea/Ea 1Ea/Ea 1Ea/Ea 1Ea/Ea 1Ea/Ea 1Ea/Ea 1Ea/Ea
1Ea/Ea 1Ea/Ea 1Ea/Ea 1Ea/Ea 1Ea/Ea 1Ea/Ea 1Ea/Ea 1Ea/Ea 1Ea/Ea (>ZDU !DJ IRIDM:TEDJ (REDACTED) !UD'tmll (l!DO<mll (l!DfCllQ
(l!DO< U!DI (lm >.C !DJ (>ZDU!!D (>ZDU!!DJ (>ZDU!!I (>ZDU!!D (UIN:D!I (>ZDU!J!Il (>ZDU!! I ,l;ll!DI'£1!J
(UIN:!l!I (>ZDU!l!I OM2193347 OM2193348 OM2193349 1 1 1 Ea Ea Ea 1Ea/Ea 1Ea/Ea 1Ea/Ea ,(UIN:!l!I !UD't') ,(UIN:!!l Ea Ea 1Ea/Ea
1Ea/Ea OM2193349 OM2193351 1 1 (l!DO<mll ,.,.,..m (l!DUrm: Ea Ea Ea Ea Ea Ea Ea Ea Ea Ea Ea Ea Ea Ea Ea 1Ea/Ea 1Ea/Ea 1Ea/Ea
1Ea/Ea 1Ea/Ea 1Ea/Ea 1Ea/Ea 1Ea/Ea 1Ea/Ea 1Ea/Ea 1Ea/Ea 1Ea/Ea 1Ea/Ea 1Ea/Ea 1Ea/Ea OM2193352 OM2193360 OM2193370 OM2196303 OM2196330
OM2196331 PS0000013 UDA2110402 UP2100300 US0060520 US0060600 US0060620 US22S0304 US22S0305 US2250306 1 1 1 1 1 1 1 1 1 1 1 1 1
1 1 (lm >.C !DJ (REDACTED) (REDACTED) (>ZDU!!DJ [REDAClED] [REDACTED) [REDACTED] lREDAClED] (REDACTED) [REDACTED] [REDAClED]
[REDACTED] [REDACTED] Master Products and Service Agreement Templa te Version - 4/26/17 (#322939-v17) 14 March 20,2019 CONFIDENTIAL

 

     

     

    

 

 

DocuSign Envelope ID: 401D7E57-BECF-4F17-A613-8D2D118C4753 EXHIBIT
B ADDITIONAL REQUIREMENTS FOR VENDORS, CONTRACTORS AND SUPPLIERS Definitions. As used herein, the following definitions shall apply:
 “Customer” means a Kaiser Permanente entity purchasing goods or services from Supplier. “KP” means the
integrated health care delivery organization doing business as Kaiser Permanente®, which includes Customer and its affiliates.
 “Supplier” means a vendor, contractor or supplier who is providing goods and/or services to a Customer. x x Vendor
Code of Conduct. KP strives to demonstrate high ethical standards in its business practices. KP’s vendors play an integral
role in making this happen. The Vendor Code of Conduct, available for review at http://supplier.kp.org/formsreqs/index.html, contains
the minimum standards by which Supplier is expected to conduct itself when providing Services to KP. Invoice and AP Requirements.
In order to facilitate timely and accurate payment of invoices, Kaiser requires vendors, contractors and suppliers to comply with
the Kaiser Permanente Invoice and Accounts Payable Requirements fully described at http://supplier.kp.org/formsreqs/index.html.
Site Access and Visitation. If Supplier is providing services at a Customer facility, Supplier will comply with all applicable
security, access, safety and fire protection regulations, Customer policies and procedures, and all applicable state and municipal
safety regulations, building codes or ordinances while performing the services under this Agreement, including, as applicable the
Vendor Visitation Policy, available for review at http://supplier.kp.org/formsreqs/index.html. Training. If Supplier provides services
at a Customer facility on a regular basis, Supplier agrees that its personnel performing services at Customer facilities shall
undergo the same training that Customer imposes on its own employees and supervisors in similar positions to ensure full compliance
with all applicable laws, regulations and KP policies. Failure of a Supplier employee to timely complete any mandatory training
course shall result in Customer removing the employee from his/her assignment. Supplier Diversity. KP has a long standing commitment
to supplier diversity. KP recognizes the benefits of inclusion and strives to ensure that minority, women and veteran owned businesses
(each a “Diverse Supplier”) are provided the maximum practical opportunity to participate in the performance of contracts.
KP’s commitment extends to the prime suppliers with whom we do business. Accordingly, we encourage our suppliers to award
subcontracts and/or utilize Diverse Suppliers where such usage is consistent with the efficient performance of this Agreement and
without compromise of quality and reliability expectations. x x x x If Supplier is a Diverse Supplier, then it must register with
KP on the KP Supplier Diversity portal at: http://xnet.kp.org/supplierdiversity/registration.html. All Suppliers, except small
businesses, that receive contracts in excess of $550,000 will be required to report their Tier II expenditures into KFH/HP’s
on-line reporting portal on a quarterly basis. "Diversity Supplier" as used herein means a business that is one or more
of the following: minority owned, women owned, veteran owned or small. x Business Associate Agreement (BAA). If Supplier will have
access to KP patient(s) protected health information as defined under HIPAA (“PHI”), Supplier must complete and sign
KP’s Business Associate Agreement. With respect to electronic PHI, Supplier must permit KP personnel to perform a security
Master Products and Service Agreement Template Version – 4/26/17 [#322939-v17] 15 March 20, 2019 CONFIDENTIAL

 

     

     

    

 

 

 

DocuSign Envelope ID: 401D7E57-BECF-4F17-A613-8D2D118C4753 risk
assessment of its facilities and systems. If Supplier will have access to PHI, Supplier represents that it will not receive or
contract with organizations that receive, process or store PHI outside of the United States, Puerto Rico, or the U.S. Territories.
Check one of the following: Business Associate Agreement (BAA) is required, has been executed, and is incorporated herein by this
reference; or Business Associate Agreement (BAA) is not required x Business Continuity Planning. Kaiser requires each supplier
to maintain and routinely test a comprehensive Business Continuity Plan to ensure appropriate and timely recovery of services to
Kaiser Permanente during times of business interruption as more fully described at http://supplier.kp.org/formsreqs/index.html.
Quality Assurance Program. If Supplier is providing goods or services to Customer that are used in a licensed or accredited healthcare
facility, Supplier shall participate in the Kaiser Permanente Quality Assurance Program, which is available for review at http://supplier.kp.org/formsreqs/index.html.
Computer System Access. If Supplier will have access to Kaiser’s computer system to perform services for a Customer, then
Supplier shall comply with the Computer System Access Requirements, which are available for review at http://supplier.kp.org/formsreqs/index.html.
Data Security Requirements. If Supplier will be accessing, generating, processing, hosting, or storing personally identifiable
information, data, or records relating to any patient, member, employee, or contractor of any Kaiser Permanente entity, then Supplier
must comply with the Data Security Requirements, which are available for review at http://supplier.kp.org/formsreqs/index.html.
Background Check. If Supplier is providing services to Customer, Supplier shall comply with the background check requirements,
which are available for review at http://supplier.kp.org/formsreqs/index.html. Drug Screening. Upon request, Supplier will comply
with Kaiser’s Drug Screening Requirements, which are available for review at http://supplier.kp.org/formsreqs/index.html.
Health Screening. If Supplier is providing Services to Customer, Supplier will comply with the health screening requirements, which
are available for review at http://supplier.kp.org/formsreqs/index.html. Travel and Expense Guidelines. If Customer has agreed
in the Agreement or SOW, as applicable, to reimburse Supplier’s travel and associated expenses, then Supplier must comply
with the Travel and Expense Guidelines, which are available for review at http://supplier.kp.org/formsreqs/index.html. Accessibility
Standards. If Supplier is providing website products/services that will be accessible to KP members, employees or the public, then
Supplier must ensure that its website products/services are accessible for users with disabilities by meeting the Web Content Accessibility
Guidelines (WCAG) 2.0, Level AA. Payment Card Industry Requirements. If supplier’s services include processing, storing,
using or transmitting payment cardholder data, then supplier will comply with the Kaiser Permanente Payment x x x x x x x x x Card
Industry Data Security Requirements, which are available for review at http://supplier.kp.org/formsreqs/index.html. Master Products
and Service Agreement Template Version – 4/26/17 [#322939-v17] 16 March 20, 2019 CONFIDENTIAL

 

     

     

    

 

 

DocuSign Envelope ID: 401D7E57-BECF-4F17-A613-8D2D118C4753 x
Environmentally Preferable Purchasing (EPP) Program. If Supplier is supplying products/equipment, Supplier must comply with the
Environmentally Preferable Purchasing Program (EPP) requirements, which are available for review at http://xnet.kp.org/compliance/supplier/ep/index.html.
Distribution and Transportation Guidelines. If supplier is supplying products or equipment, Supplier must use reasonable efforts
to comply with the Distribution and Transportation Guidelines, which are available for review at: http://supplier.kp.org/formsreqs/index.html.
GS1® Healthcare Requirements for Vendors, Contractors and Suppliers. If Supplier is supplying x x medical device products,
Supplier must comply with the GS1® Healthcare Requirements, which are available for review at http://supplier.kp.org/formsreqs/index.html.
Master Products and Service Agreement Template Version – 4/26/17 [#322939-v17] 17 March 20, 2019 CONFIDENTIAL

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}]]